Details of the Drug

General Information of Drug (ID: DMYZ57N)

Drug Name
Albendazole
Synonyms
Albendazol; Albendazolum; Albendoral; Albenza; Bendapar; Bilutac; Digezanol; Disthelm; Endoplus; Eskazole; Gascop; Lurdex; Metiazol; Proftril; Valbazen; Zental; Zentel; Albendazole Armstrong Brand; Albendazole Diba Brand; Albendazole Fustery Brand; Albendazole Hormona Brand; Albendazole Liferpal Brand; Albendazole Monohydrochloride; Albendazole Pfizer Brand; Albendazole Sanicoopa Brand; Albendazole Valdecasas Brand; Armstrong Brand of Albendazole; Diba Brand of Albendazole; Fustery Brand of Albendazole; Hormona Brand of Albendazole; Liferpal Brand of Albendazole; Mediamix V Disthelm; Noe Socopharm Brand of Albendazole; Pfizer Brand of Albendazole; Sanicoopa Brand of Albendazole; SmithKline Beecham Brand of Albendazole; Valdecasas Brand of Albendazole; SKF 62979; SKF62979; Albendazol [INN-Spanish]; Albendazole Noe-Socopharm Brand; Albendazolum [INN-Latin]; Albenza (TN); Disthelm, Mediamix V; Eskazole (TN); Monohydrochloride, Albendazole; Noe-Socopharm Brand of Albendazole; SK&F 62979; SK&F62979; SKF-62979; Smith Kline & French Brand of Albendazole; V Disthelm, Mediamix; Zentel (TN); SK&F-62979; Albendazole (JAN/USP/INN); Albendazole [USAN:INN:BAN:JAN]; Albenza, Eskazole, Zentel, Andazol, Albendazole; Methyl 5-(propylthio)-2-benzimidazolecarbamate; Methyl [5-(Propylthio)benzimidazol-2-yl]carbamate; Methyl-5-[propylthio]-2-benzimidazole carbamate; [5-(Propylthio)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl 5-(propyl-thio)-2-benzimidazolecarbamate; Methyl [5-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; Methyl [5-(propylthio)-1H-benzimidazol-2-yl]carbamate; Methyl [6-(propylsulfanyl)-1H-benzimidazol-2-yl]carbamate; [5-(Propythio)-1H-benzimidazol-2-yl]carbamic acid methyl ester; MethylN-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate; O-Methyl N-(5-(propylthio)-2-benzimidazolyl)carbamate; Carbamic acid, [5-(propylthio)-1H-benzimidazol-2-yl]-, methyl ester; Methyl N-[6-(propylsulfanyl)-1H-1,3-benzodiazol-2-yl]carbamate; CARBAMIC ACID, (5-(PROPYLTHIO)-1H-BENZIMIDAZOL-2-YL)-, METHYL ESTER; Methyl [(2Z)-5-(propylsulfanyl)-1,3-dihydro-2H-benzimidazol-2-ylidene]carbamate; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle; ((Propylthio)-5 1H-benzimidazolyl-2) carbamate de methyle [French]; (5-(Propylthio)-1H-benzimidazol-2-yl)carbamic acid methyl ester; (5-Propylsulfanyl-1H-benzoimidazol-2-yl)-carbamic acid methyl ester; 5-(Propylthio)-2-carbomethoxyaminobenzimidazole
Indication
Disease Entry ICD 11 Status REF
Worm infection 1F90.Z Approved [1]
Therapeutic Class
Antiprotozoal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 265.33
Topological Polar Surface Area (xlogp) 2.9
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Elimination
0% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 - 12 hours [3]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 56.53 micromolar/kg/day [5]
Chemical Identifiers
Formula
C12H15N3O2S
IUPAC Name
methyl N-(6-propylsulfanyl-1H-benzimidazol-2-yl)carbamate
Canonical SMILES
CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC
InChI
InChI=1S/C12H15N3O2S/c1-3-6-18-8-4-5-9-10(7-8)14-11(13-9)15-12(16)17-2/h4-5,7H,3,6H2,1-2H3,(H2,13,14,15,16)
InChIKey
HXHWSAZORRCQMX-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2082
ChEBI ID
CHEBI:16664
CAS Number
54965-21-8
DrugBank ID
DB00518
TTD ID
D00KVO
VARIDT ID
DR01323
INTEDE ID
DR0055
ACDINA ID
D00015

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin beta (TUBB) TTYFKSZ NOUNIPROTAC Binder [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Albendazole (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Arn-509 DMT81LZ Moderate Increased metabolism of Albendazole caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [55]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Albendazole caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [56]
Voriconazole DMAOL2S Moderate Decreased metabolism of Albendazole caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [57]
Posaconazole DMUL5EW Moderate Decreased metabolism of Albendazole caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [55]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Albendazole caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [58]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Albendazole caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [59]
Tucatinib DMBESUA Moderate Decreased metabolism of Albendazole caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [60]
Levobupivacaine DM783CH Minor Increased metabolism of Albendazole caused by Levobupivacaine mediated induction of CYP450 enzyme. Corneal disease [9A76-9A78] [61]
Mifepristone DMGZQEF Moderate Decreased metabolism of Albendazole caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [57]
Ivacaftor DMZC1HS Moderate Decreased clearance of Albendazole due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [62]
MK-8228 DMOB58Q Moderate Decreased metabolism of Albendazole caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [63]
Aprepitant DM053KT Moderate Decreased metabolism of Albendazole caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [64]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Albendazole caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [65]
Cenobamate DMGOVHA Moderate Increased metabolism of Albendazole caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [66]
Stiripentol DMMSDOY Moderate Decreased metabolism of Albendazole caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Rufinamide DMWE60C Moderate Increased metabolism of Albendazole caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [55]
Tazemetostat DMWP1BH Moderate Increased metabolism of Albendazole caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [68]
Itraconazole DMCR1MV Moderate Decreased metabolism of Albendazole caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [69]
Boceprevir DMBSHMF Moderate Decreased metabolism of Albendazole caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [70]
Telaprevir DMMRV29 Moderate Decreased metabolism of Albendazole caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [71]
Rifapentine DMCHV4I Moderate Increased metabolism of Albendazole caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [72]
Fosamprenavir DM4W9B3 Moderate Decreased metabolism of Albendazole caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Cobicistat DM6L4H2 Moderate Decreased clearance of Albendazole due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [74]
Efavirenz DMC0GSJ Moderate Increased metabolism of Albendazole caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [75]
Saquinavir DMG814N Moderate Decreased metabolism of Albendazole caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [76]
Etravirine DMGV8QU Moderate Increased metabolism of Albendazole caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [77]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Albendazole caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Conivaptan DM1V329 Moderate Decreased metabolism of Albendazole caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [78]
Tasimelteon DMLOQ1V Moderate Increased metabolism of Albendazole caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [79]
Brigatinib DM7W94S Moderate Increased metabolism of Albendazole caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [80]
PF-06463922 DMKM7EW Moderate Increased metabolism of Albendazole caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [81]
Selpercatinib DMZR15V Moderate Decreased metabolism of Albendazole caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [55]
Idelalisib DM602WT Moderate Decreased metabolism of Albendazole caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [82]
IPI-145 DMWA24P Moderate Decreased metabolism of Albendazole caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [83]
Arry-162 DM1P6FR Moderate Increased metabolism of Albendazole caused by Arry-162 mediated induction of CYP450 enzyme. Melanoma [2C30] [57]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Albendazole caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [55]
Exjade DMHPRWG Moderate Decreased metabolism of Albendazole caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [84]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Albendazole and Ocrelizumab. Multiple sclerosis [8A40] [85]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Albendazole caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [55]
Nilotinib DM7HXWT Moderate Decreased clearance of Albendazole due to the transporter inhibition by Nilotinib. Myeloproliferative neoplasm [2A20] [86]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Albendazole and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [87]
Modafinil DMYILBE Minor Increased metabolism of Albendazole caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [88]
Entrectinib DMMPTLH Moderate Decreased metabolism of Albendazole caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [89]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Albendazole caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [90]
Abametapir DM2RX0I Moderate Decreased metabolism of Albendazole caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [91]
Lefamulin DME6G97 Moderate Decreased metabolism of Albendazole caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [92]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Albendazole caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [93]
Enzalutamide DMGL19D Moderate Increased metabolism of Albendazole caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [94]
Bosentan DMIOGBU Moderate Increased metabolism of Albendazole caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [95]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Albendazole and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [96]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Albendazole caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [97]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Albendazole caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [55]
Larotrectinib DM26CQR Moderate Decreased metabolism of Albendazole caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [57]
Armodafinil DMGB035 Minor Increased metabolism of Albendazole caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
LEE011 DMMX75K Moderate Decreased metabolism of Albendazole caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [98]
Pitolisant DM8RFNJ Moderate Increased metabolism of Albendazole caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [55]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Albendazole caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [99]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Albendazole and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [96]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Albendazole and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [96]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Albendazole and Ganciclovir. Virus infection [1A24-1D9Z] [57]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Albendazole and Valganciclovir. Virus infection [1A24-1D9Z] [57]
⏷ Show the Full List of 61 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 30 E00456 3000709 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sucralose E00370 71485 Flavoring agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Saccharin sodium monohydrate E00417 443755 Flavoring agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Albendazole 200 mg tablet 200 mg Chewable Tablet Oral
Albendazole 200 mg tablet 200 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
2 BDDCS applied to over 900 drugs
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
7 The anthelminthic agent albendazole does not interact with p-glycoprotein. Drug Metab Dispos. 2002 Apr;30(4):365-9.
8 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
9 Danazol inhibits cytochrome P450 2J2 activity in a substrate-independent manner. Drug Metab Dispos. 2015 Aug;43(8):1250-3.
10 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
21 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
22 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
23 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
24 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
25 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
26 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
27 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
28 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
29 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
30 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
31 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
32 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
35 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
36 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
37 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
38 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
39 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
40 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
41 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
42 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
43 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
44 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
45 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
46 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
47 Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
48 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
49 NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
50 Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
51 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
52 Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
53 The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.
54 National Cancer Institute Drug Dictionary (drug id 598799).
55 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
56 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
57 Cerner Multum, Inc. "Australian Product Information.".
58 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
59 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
60 Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
61 Product Information. Chirocaine (levobupivacaine) Organon, West Orange, NJ.
62 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
63 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
64 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
65 Product Information. Trileptal (oxcarbazepine) Novartis Pharmaceuticals, East Hanover, NJ.
66 Product Information. Xcopri (cenobamate). SK Life Science, Inc., Paramus, NJ.
67 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
68 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
69 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
70 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
71 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
72 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
73 Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
74 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
75 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
76 Product Information. Fortovase (saquinavir) Roche Laboratories, Nutley, NJ.
77 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
78 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
79 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
80 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
81 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
82 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
83 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
84 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
85 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
86 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
87 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
88 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
89 Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
90 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
91 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
92 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
93 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
94 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
95 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
96 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
97 Product Information. Oxbryta (voxelotor). Global Blood Therapeutics, Inc., South San Francisco, CA.
98 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
99 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.